ג'נדברה - Gendevra

Gendevra is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:• In adults and adolescents aged from 12 years and with body weight at least 35 kg• In children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.